Session Information
-
WCLC 2017
18th World Conference on Lung Cancer
Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan
Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18
-
+
P1.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
-
+
P1.01-051 - Nivolumab Versus Chemotherapy as Post-Platinum Therapy for Advanced Non-Small Cell Lung Cancer in a Real-world Setting
09:30 - 09:30 | Presenter: Edward Brian Garon | Author(s): M. Moezi, J. Chandler, D. Waterhouse, S. Wilks, D. Richards, M. Hussein, David R Spigel, V. Gunuganti, M.D. Danese, M. Gleeson, D. Lubeck, V. Burns, B. Korytowsky, C. Batenchuk, R. Jotte
- Abstract
Loading...
-
+
P1.04 - Clinical Design, Statistics and Clinical Trials
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
-
+
P1.04-008 - POSEIDON: A Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC
09:30 - 09:30 | Presenter: Tony SK Mok | Author(s): M.L. Johnson, Edward Brian Garon, Solange Peters, J. Soria, L. Wang, A. Jarkowski, P.A. Dennis, Caicun Zhou
- Abstract
Loading...
-
+
MA 02 - Emerging Targets
- 11:00 - 12:30
- 10/16/2017
- Location: Room 511 + 512
- Type: Mini Oral
- Track: Clinical Design, Statistics and Clinical Trials
- Moderators:Ravi Salgia, Shun Lu
-
+
MA 02.07 - A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC
11:40 - 11:45 | Presenter: Aaron Lisberg | Author(s): J. Hunt, N. Reese, T. Wang, P. Coluzzi, M. Spiegel, K. Bornazyan, J. Carroll, J. Madrigal, B. Ledezma, M. Mendenhall, J.L. Bui, H. Lu, A. Cummings, Z. Noor, Jonathan W. Goldman, Edward Brian Garon
- Abstract
Loading...
-
+
MA 03 - Chemotherapy
- 11:00 - 12:30
- 10/16/2017
- Location: Room 502
- Type: Mini Oral
- Track: Advanced NSCLC
- Moderators:Jin-Hyoung Kang, W. Su
-
+
MA 03.06 - Effect of 2L Ramucirumab after Rapid Time to Progression on 1L Therapy: Subgroup Analysis of REVEL in Advanced NSCLC
11:35 - 11:40 | Presenter: Martin Reck | Author(s): Frances A Shepherd, Maurice Pérol, Frederico Cappuzzo, J. Shih, Keunchil Park, K.B. Winfree, E. Alexandris, P. Lee, A. Sashegyi, Edward Brian Garon
- Abstract
Loading...
-
+
P2.04 - Clinical Design, Statistics and Clinical Trials
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
-
+
P2.04-005 - GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR Wt, MET-Dysregulated Advanced NSCLC
09:30 - 09:30 | Presenter: Jürgen Wolf | Author(s): Ji-Youn Han, Makoto Nishio, P. Souquet, Luis Paz-Ares, F. De Marinis, Takashi Seto, M. De Jonge, T.M. Kim, Johan F. Vansteenkiste, Daniel SW Tan, Edward Brian Garon, H.J. Groen, Maximilian Johannes Hochmair, Enriqueta Felip, Noemi Reguart, M. Thomas, T.R. Overbeck, K. Ohashi, M. Giovannini, R. Yura, A. Joshi, M. Akimov, R. Heist
- Abstract
Loading...
-
+
P2.07 - Immunology and Immunotherapy
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
-
+
P2.07-038 - Thyroid Dysfunction Arising During KEYNOTE-001 Associated with Improved Efficacy of Pembrolizumab in NSCLC Patients at UCLA
09:30 - 09:30 | Presenter: Aaron Lisberg | Author(s): K. Bornazyan, J. Madrigal, J.L. Bui, J. Carroll, C. Adame, J. Hunt, H. Lu, Z. Noor, A. Cummings, Jonathan W. Goldman, Edward Brian Garon
- Abstract
Loading...
-
+
GR 02 - Management of Immunotherapy-Related Adverse Events
- 11:00 - 12:30
- 10/17/2017
- Location: Main Hall
- Type: Grand Rounds
- Track: Immunology and Immunotherapy
- Moderators:Edward Brian Garon, Makoto Nishio
-
+
GR 02.00 - Intro
11:00 - 11:02 | Presenter: Makoto Nishio
- Abstract
No abstract available for this presentation
-
+
GR 02.01 - Case Study
11:02 - 11:07 | Presenter: Edward Brian Garon
- Abstract
No abstract available for this presentation
-
+
GR 02.02 - Case Study
11:07 - 11:12 | Presenter: Makoto Nishio
- Abstract
No abstract available for this presentation
-
+
GR 02.03 - Pathophysiology of Immunotherapy-related Toxicity
11:12 - 11:27 | Presenter: Ji-Youn Han
- Abstract
Loading... -
+
GR 02.04 - Current Standard in Monitoring of Immunotherapy-related Toxicity
11:27 - 11:42 | Presenter: Clarissa Mathias
- Abstract
Loading... -
+
GR 02.05 - Practical Management of Immunotherapy-related Toxicity
11:42 - 11:57 | Presenter: Scott N. Gettinger
- Abstract
No abstract available for this presentation
-
+
GR 02.06 - Who Should Not Receive Immunotherapy?
11:57 - 12:12 | Presenter: Terufumi Kato
- Abstract
No abstract available for this presentation
-
+
GR 02.07 - Toxicity of Induction Immunotherapy Followed by Radiotherapy: How to Minimize It?
12:12 - 12:27 | Presenter: Dirk K De Ruysscher
- Abstract
Loading... -
+
GR 02.08 - Q&A
12:27 - 12:32
- Abstract
No abstract available for this presentation
-
+
MTE 28 - Immunotherapy for Earlier Stage NSCLC (Sign Up Required)
- 07:00 - 08:00
- 10/18/2017
- Location: Room 301 + 302
- Type: Meet the Expert
- Track: Immunology and Immunotherapy
-
+
MTE 28.02 - Pros and Cons of IO in Early Stage NSCLC
07:30 - 08:00 | Presenter: Edward Brian Garon
- Abstract
No abstract available for this presentation
-
+
P3.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
-
+
P3.01-071 - Randomized Phase 1b/3 Study of Erlotinib + Ramucirumab in Untreated EGFR Mutation-Positive Stage IV NSCLC: Phase 1b Outcomes
09:30 - 09:30 | Presenter: Kazuhiko Nakagawa | Author(s): Edward Brian Garon, Luis Paz-Ares, S. Ponce, J. Corral Jaime, O. Juan Vidal, Ernest Nadal, K. Kiura, Keunchil Park, R.C. Widau, E. Alexandris, S. He, P. Lee, Martin Reck
- Abstract
Loading...
-
+
P3.03 - Chemotherapy/Targeted Therapy
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
-
+
P3.03-007 - LCMC2: Expanded Profiling of Lung Adenocarcinomas Identifies ROS1 and RET Rearrangements and TP53 Mutations as a Negative Prognostic Factor
09:30 - 09:30 | Presenter: Mark G Kris | Author(s): D.L. Aisner, L.M. Sholl, L.D. Berry, M. Rossi, H. Chen, J. Fujimoto, Andre L. Moreira, Suresh S Ramalingam, L.C. Villaruz, G. Otterson, E. Haura, K. Politi, B. Glisson, J. Cetnar, Edward Brian Garon, Joan Schiller, S.N. Waqar, Lecia V Sequist, Julie R Brahmer, Yu Shyr, K. Kugler, Ignacio I. Wistuba, B.E. Johnson, J. Minna, Paul A. Bunn, Jr., D.J. Kwiatkowski
- Abstract
Loading...